Immunovant IMVT
NASDAQ IMVT
$37.04 +1.33 (+3.72%)
At close: Nov 11, 2026 · 4:00 PM EST

Immunovant (IMVT) Return on Capital Employed [ROCE] (2019 - 2026)

Updated

Immunovant's Return on Capital Employed [ROCE] came in at -68.42% for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 1.51 percentage points from -66.91% a year earlier and down 12.28 percentage points from the prior quarter.

Analysis

Immunovant (IMVT) Return on Capital Employed [ROCE] (2019 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Immunovant's Return on Capital Employed [ROCE] was -66.31%, down 3.02 percentage points from FY2025.

  • Return on Capital Employed [ROCE] has declined in each of the last four fiscal years, with a five-year change of -21.80 percentage points (FY2021 to FY2026).
  • Going back by fiscal year, Return on Capital Employed [ROCE] was -63.29% in FY2025 (-10.20 pp), -53.08% in FY2024 (-2.54 pp), -50.54% in FY2023 (-13.16 pp) and -37.38% in FY2022 (+7.13 pp).
  • The five-year range for quarterly Return on Capital Employed [ROCE] is -95.54% (fiscal Q3 2025) to -26.58% (fiscal Q3 2022).
  • Year-over-year, Return on Capital Employed [ROCE] increased in three of the last eight quarters, with an average year-over-year change of -4.85 percentage points.
  • The fastest year-over-year change in Return on Capital Employed [ROCE] over five years came in fiscal Q3 2026 (a gain of 34.25 percentage points), and the weakest in fiscal Q2 2024 (a drop of 47.95 percentage points).
  • Business Quant data shows IMVT's Return on Capital Employed [ROCE] at -56.14% (Q4 2026), -61.29% (Q3 2026) and -82.74% (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Immunovant 7.38 Bn 3.97 Bn - -72.61%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -72.61%
Jun 30, 2026 -68.42%
Mar 31, 2026 -56.14%
Dec 31, 2025 -61.29%
Sep 30, 2025 -82.74%
Jun 30, 2025 -66.91%
Mar 31, 2025 -77.94%
Dec 31, 2024 -95.54%
Sep 30, 2024 -66.40%
Jun 30, 2024 -46.64%
Mar 31, 2024 -40.41%
Dec 31, 2023 -51.98%
Sep 30, 2023 -90.77%
Jun 30, 2023 -74.85%
Mar 31, 2023 -54.40%
Dec 31, 2022 -49.31%
Sep 30, 2022 -42.82%
Jun 30, 2022 -35.70%
Mar 31, 2022 -32.34%
Dec 31, 2021 -26.58%
API Access

Immunovant Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=IMVT&period=max&api_key=YOUR_API_KEY